The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.
The European Medicines Agency safety committee (PRAC) has concluded that Xeljanz (tofacitinib - TOFA) could increase the risk of blood clots in the lungs and in deep veins in patients who are already at high risk for venous thromboembolic events. The PRAC is recommending that TOFA should be used with caution in patients at high risk of blood clots (VTE), regardless of dose used.
The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).
It’s hard work wearing a crown. The dermatologists have been dethroned as Medscape’s happiest specialty after years at the top. While studies only detail that we are the most satisfied outside of work, I argue we are the happiest working, too.
With an N of 1, here are my 10 observations.
The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX).
A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.
The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (
Gilead has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis (RA).
Millennial physicians comprise a wider, diverse population compared to prior generations, including an ever-increasing female physician community. It is estimated that by 2025, 75% of the work force will be millennials.1 This generation grew up in an era of participation trophies and structured childhood schedules, all while watching their predecessors sacrifice work/life balance due to persistent slashing of reimbursement. All of this sets the
Dr. Jack Cush reviews the news from the past week on RheumNow.com, just in time for Christmas!
Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.
Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by trial of belimumab for the treatment of active lupus nephritis in adult patients.
The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.
French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.
At the recent ACR 2019 meeting, I met some incredible women who shared with me their struggles, sacrifices and success when it comes to balancing a career and family while still retaining their sense of self. Many of you know I am a mother to 3 children ages 15, 12 and 9. Life can be challenging, especially since my husband has a busy practice, too. So how do you advance your career and still raise a family? Here are five lessons I've learned.
